Intercept Pharmaceuticals Stock News

ENERTIME (FR0011915339 - ALENE), société française des « CleanTech » au service de l'efficacité énergétique industrielle et de la production d'énergie renouvelable décentralisée (biomasse e

Intercept Pharmaceuticals (NASDAQ:ICPT)‘s stock had its “buy” rating reissued by investment analysts at Wedbush in a research report issued to clients and investors on Monday, TipRanks reports.

Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by analysts at Cowen from an “outperform” rating to a “market perform” rating in a note issued to investors on Monday, Marketbeat reports

Google has done a great job squeezing an impressive OLED display into the midrange Pixel 3a, so the least you can do is add some protection that will keep it safe while you're out and about. Protect a

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc.

Uncertainty over its NASH drug weighs on the stock.

Intercept (ICPT) down on receipt of CRL for its NDA seeking approval of OCA for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).

Companies in the news are: KNSA, TLSA, COTY, ICPT

The Iowa senator’s comments could signal that there is little chance for a bill this year that would rein in drug prices, a policy that voters have expressed keen interest in.

In a report released today, Alan Carr from Needham assigned a Buy rating to Intercept Pharma (ICPT – Research Report),

Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection.